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Abstract
Background: The AMI code is a regional network enhancing a rapid and widespread access to reperfusion therapy
(giving priority to primary angioplasty) in patients with acute ST-segment elevation myocardial infarction (STEMI).
We aimed to assess the long-term control of conventional cardiovascular risk factors after a STEMI among patients
included in the AMI code registry.
Design and methods: Four hundred and fifty-four patients were prospectively included between June-2009 and
April-2013. Clinical characteristics were collected at baseline. The long-term control of cardiovascular risk factors and
cardiovascular morbidity/mortality was assessed among the 6-months survivors.
Results: A total of 423 patients overcame the first 6 months after the STEMI episode, of whom 370 (87%) underwent
reperfusion therapy (363, 98% of them, with primary angioplasty). At 1-year follow-up, only 263 (62%) had adequate
blood pressure control, 123 (29%) had LDL-cholesterol within targeted levels, 126/210 (60%) smokers had withdrawn
from their habit and 40/112 (36%) diabetic patients had adequate glycosylated hemoglobin levels. During a median
follow-up of 20 (11–30) months, cumulative mortality of 6 month-survivors was 6.1%, with 9.9% of hospital
cardiovascular readmissions. The lack of assessment of LDL and HDL-cholesterol were significantly associated with
higher mortality and cardiovascular readmission rates.
Conclusions: Whereas implementation of the AMI code resulted in a widespread access to rapid reperfusion therapy,
its long-term therapeutic benefit may be partially counterbalanced by a manifestly suboptimal control of cardiovascular
risk factors. Further efforts should be devoted to secondary prevention strategies after STEMI.
Keywords: ST-segment elevation myocardial infarction, Coronary angioplasty, Secondary prevention, Prognosis,
Reperfusion therapy, Cardiovascular risk factors
Background
Case-fatality and long-term mortality after an acute
myocardial infarction (AMI) has manifestly decreased
over the last decades. Both the use of more effective
pharmacological and revascularization strategies account
for this decrease [1–4]. However, coronary artery disease
(CAD) continues to be the most determinant cause of mor-
tality in high-income societies [5]. ST-segment elevation
myocardial infarction (STEMI) is one of the main clinical
manifestations of CAD, and rapid (<12 h) coronary reperfu-
sion continuous to be the main therapeutic goal to enhance
a favorable cardiovascular outcome after the index coronary
event. In this scenario, primary percutaneous coronary
intervention (PCI) is nowadays preferred over fibrinolysis,
especially when the coronary intervention is performed
within the first 120 min [6–8].
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Regardless of such rapid therapeutic interventions, the
readmission and mortality rates after the index AMI
episode are not negligible, with an 8–20% of the patients
being readmitted and 10% of them dying within the first
year [9–13]. Previous reports have postulated that the sub-
optimal cardiovascular morbidity and mortality rates after
an acute coronary event may be related to an inadequate
control of the cardiovascular risk factors (secondary
prevention strategies) [14–17]. However, assessment of
the long-term degree of implementation and adherence to
such secondary prevention strategies in STEMI patients
undergoing urgent reperfusion in the era of widespread
use of PCI is scarce in the literature [18–21].
In this study, we aimed to assess the long-term control
of conventional cardiovascular risk factors in patients pre-
senting with acute STEMI undergoing urgent reperfusion
therapy, with urgent PCI designated as the preferred
therapeutic strategy. We further analyzed the prognostic
impact of an inadequate control of such risk factors.
Methods
Patient population: the AMI code program
A total of 467 consecutive STEMI patients referred to our
hospital from June 2009 to April 2013 within the AMI
code program were prospectively considered for inclusion.
The AMI code program, created in 2009, consists of a
regional network developed in Catalonia (Spain) aiming to
provide a rapid and widespread access to PCI among pa-
tients presenting with an acute STEMI [8]. More precisely,
it consists of an integrated assistance network for urgent
action that coordinates primary health centers, ‘non-PCI-
available’ hospitals, ‘PCI-available’ hospitals and mobile
emergency assistance units. Upon the diagnosis of STEMI,
the AMI code is activated and primary PCI (to be
performed in a preliminary designated ‘PCI-available’
institution) is set up, provided that the time interval
between the onset of symptoms and the percutaneous
intervention is presumed to be within the therapeutic win-
dow. Additionally, the AMI code can be activated for those
patients without apparent myocardial reperfusion after
pharmacological fibrinolysis (rescue angioplasty). Twenty-
four to forty-eight hours after the index STEMI episode,
in the absence of acute complications, patients are
planned to be discharged to their reference hospital.
Patients not established in Catalonia (tourists and
displaced) were excluded from the analysis upon a
presumably suboptimal follow-up.
The study was designed and implemented in accordance
with Guidelines for Good Clinical Practice and with the
ethical principles laid down in the Declaration of Helsinki.
In-hospital data collection
Demographic (age, gender) and clinical characteristics
(infarct location, systolic blood pressure, Killip class at
admission and left ventricular ejection fraction), as well
as history and control of cardiovascular risk factors
(smoking, dyslipidemia, hypertension and diabetes melli-
tus) and other comorbidities (personal and family history
of ischemic cardiomyopathy, chronic kidney disease,
anemia) were collected at the time of patient’s hospital
admission during the index STEMI episode. The lipid
profile, glomerular filtration rate and the glycosylated
hemoglobin levels were analyzed at baseline. In-hospital
morbidity and mortality, the pharmacological therapy
administered during admission and the primary PCI
procedure findings were also collected.
Clinical follow-up
The clinical follow-up after final hospital discharge was
carried out by the primary care physician or through the
cardiologist outpatient clinic/primary health center at the
reference physician’s discretion. After hospital discharge,
assessment and control of the cardiovascular risk factors
and the patient’s clinical outcome were monitored and in-
corporated into the study database through the Catalonia’s
regional electronic health recording system, in which the
patient’s clinical status, the rate of hospital readmissions
after the index STEMI event, the pharmacological intake,
the laboratory test and radiology results were available for
the study purposes. Overall mortality was ensured by
means of consultation of the National Death Registry.
Heart failure, acute coronary syndrome and stroke were
considered cardiovascular readmission. Following
previously reported definitions, stroke was considered a
cardiovascular condition in the assessment of the clinical
outcome after STEMI [22–24]. Direct telephone contact
with the patient was allowed in order to fulfill any missing
data from the electronic health recording system.
The long-term control of conventional cardiovascular
risk factors was exclusively analyzed for those patients
who survived at least the first 6 months after the index
STEMI episode. By these means, any bias in the results
obtained related to a suboptimal risk factor control dur-
ing the very initial phases after the STEMI would be
avoided. A minimum 6-months follow-up period was
considered compelling for the surviving study patients
in order to enhance a truly long-term assessment of the
efficiency of secondary prevention strategies in this
population.
Assessment of the adequate implementation secondary
prevention strategies (i.e. pharmacological intake, smoking
habit withdrawal, blood pressure, glycosylated hemoglobin,
triglyceride and cholesterol levels) was performed
12 months after the index STEMI episode. The closest la-
boratory and blood pressure values were retrieved by means
of manual review of the patient’s electronic clinical
history. A 6 to 18-month timeframe from the STEMI
was allowed for the obtainment of such clinical and
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laboratory variables, following previously reported
methodology [10, 14, 15, 18–20]. As for patients who
died between the 6 months and the first year after the
STEMI, the latest risk factors assessment before their
decease was incorporated into the study database.
Adequate control of cardiovascular risk factors was
established, following current guidelines, as follows: blood
pressure <140/90 mmHg; smoking abstinence for at least
6 months; total cholesterol of <200 mg/dL, LDL-
cholesterol of <70 mg/dL or ≥50% lower with respect to
baseline values, HDL-cholesterol >40 mg/dL and triglycer-
ides below 150 mg/dL [18–21, 25–28]. Glycosylated
hemoglobin levels of <7.5% were pursued among diabetic
study patients [18–21, 26].
Our institutional guidelines and recommendations
include that all patients should undergo a cardiovascular
risk factors assessment during the first year after the index
STEMI event and assuming that this information was
available in the regional electronic health recording sys-
tem, a particular risk factor was considered: i) controlled
when the targeted goal was achieved; ii) not controlled
when the targeted goal was not achieved; and iii) not
assessed when no information related to the risk factor
was available in the electronic health record system.
A longer follow-up study period (beyond the 12-months
study period) was allowed for the assessment of mortality
and cardiovascular readmission rates.
Statistical analysis
Results are expressed as absolute and relative frequencies
for categorical variables, as means and standard deviations
(SD) or, when appropriate, as medians and interquartile
ranges (IQR), for continuous variables. Student’s T-test or
Man-Whitney U test was used for the comparison of
quantitative variables and the chi-squared was used for
the comparison of qualitative variables. A multinomial
multivariate analysis was carried out in order to identify
those clinical variables associated with an adequate con-
trol of the cardiovascular risk factors in our population.
Finally, in order to assess the influence of risk factors con-
trol in the long-term prognosis of our population, a Cox
proportional hazard regression model was used. Those
variables associated with the outcomes of interest in the
univariate analysis (p-value < 0.05) were included in the
multivariate models, moreover we also included age, as a
continuous variable, and sex. All analyses were performed
using the R statistical package.
Results
Patient population
Out of the 467 STEMI patients consecutively admitted
in our Institution upon activation of the AMI code, 13
were excluded because they were foreigners/displaced.
Of the remaining 454 patients, 433 (95%) survived the
first 30 days and 423 (93%) survived the first 6 months,
the latter comprising our study population (Fig. 1). The
percentage of missing data was null for the main
variables of interest (control of cardiovascular risk
factors and clinical outcomes in the follow-up) and < 5%
for the covariates included in the multivariate analyses.
The clinical and demographic baseline characteris-
tics of the 6-month surviving 423 patients are shown
in Table 1. Of note, urgent reperfusion therapy was
performed in 370 (87%) patients, in nearly all 363/370
(98%) by means of primary PCI. In the remaining
seven patients (2%), fibrinolysis was preferred upon a
presumably delayed access to urgent PCI. An exces-
sively delayed time from the onset of symptoms until
first medical attendance was the principal reason for
reperfusion therapy not being carried out (53 out of
the 423 patients not undergoing urgent reperfusion,
13%). The median time between first medical contact
and reperfusion was 94 (69–128) minutes. The
pharmacological treatment administered during the
procedure and the hospital admission, as well as the
in-hospital complications are summarized in
Additional file 1: Table S1.
Cardiovascular risk factors at 1-year follow-up
Remarkably, ongoing pharmacological secondary pre-
vention strategies was the rule among the study
population, with 95% of the patients receiving statins,
90% on acetylsalicylic acid, 86% on beta-blockers and
78% on ACE inhibitors or ARBs at the end of the
follow-up period.
Assessment of cardiovascular risk factors at 1-year
follow-up is summarized in Fig. 2 and Table 2. Blood
pressure and LDL-Cholesterol levels were not
assessed in 84 (20%) and 93 (22%) patients, respect-
ively (Fig. 2). Smoking habit withdrawal was not
assessed in 41 out of the 201 smokers (20%) included
Fig. 1 Study patient’s flow-chart
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in the study. Finally, in 38 out of the 112 diabetic
patients (34%), the glycosylated hemoglobin was not
available (Fig. 2). In those patients with a proper
assessment of cardiovascular risk factors, a significant
descent of total cholesterol (from 184 [179–188] to
155 [151–159] mg/dL, p < 0.001), LDL-cholesterol
(112 [108–116] to 86 [82–89] mg/dL, p < 0.001) and
triglycerides levels (from 120 [88–168] to 105 [81–150]
mg/dL, p < 0.001) was observed. However, only 29% of
patients had their LDL-cholesterol values below the tar-
geted levels 1 year after the STEMI episode (Fig. 2).
No significant changes in HDL-cholesterol levels were
observed (p = 0.699). Nearly two-thirds of patients
(263 patients, 62%) had an adequate blood pressure
control and a significant descent in systolic blood pressure
was observed from hospital admission to 1 year after the
STEMI (133 [130–136] to 126 [124–128] mmHg, p <
0.001). As for diabetic patients, the glycosylated








Age (years) 63 ± 13.1 60.9 ± 12.7 69.2 ± 12.4 <0.001
Current smokers 201 (47.9%) 173 (54.4%) 28 (27.5%) <0.001
Former smokers (>1 year) 100 (23.8%) 92 (28.9%) 8 (7.8%) <0.001










Diabetes mellitus 112 (26%) 76 (24%) 36 (35%) 0.107
Family historya 39 (11%) 29 (10.5%) 10 (12.3%) 0.800
Previous ischemic heart disease 44 (10.4%) 35 (11%) 9 (8.7%) 0.626
Chronic kidney disease 14 (3.4%) 7 (2.3%) 7 (6.9%) 0.052
Anemia 33 (8.2%) 19 (6.3%) 14 (14.1%) 0.023
AMI data
Systolic blood pressure at admission (mmHg) 130 [114–150] 130 [112–148] 140 [120–164] 0.003
Infarct location 0.713
Anterior 151 (35.7%) 112 (35.1%) 39 (37.5%)
Inferior 231 (54.6%) 178 (55.8%) 53 (51%)
Killip class 0.137
I 341 (83.2%) 264 (84.9%) 77 (77.8%)
II 35 (8.1%) 22 (7.1%) 11 (11.1%)
III 16 (3.9%) 9 (2.9%) 7 (7.1%)
IV 21 (4.9%) 16 (5.1%) 4 (4.1%)
LVEF 52.1 ± 12 52,5 ± 12 51 ± 12 0.283







Hb (gr/dL) 14 ± 1.8 14.4 ± 1.7 12.9 ± 1.7 <0.001
GFR (mL/min/m2) 60 [60–60] 60 [60–60] 60 [60–60] 0.006
Basal glucose (mg/dL) 111 [98–136] 110 [98–133] 114 [97–148] 0.423
HbA1c (%) (in DM) 7.25 [6.60–8.53] 7.30 [6.60–8.53] 7.10 [6.60–8.08] 0.643
Total Cholesterol (mg/dL) 183 [150–214] 182 [151–212] 188 [150–219] 0.425
LDL-Cholesterol (mg/dL) 112 [84–139] 112 [85–138] 112 [82–142] 0.842
HDL-Cholesterol (mg/dL) 44 [37–53] 42 [36–50] 49 [41–60] <0.001
Triglycerides (mg/dL) 120 [88–168] 124 [91–173] 112 [80–159] 0.061
Results are expressed as n (%), mean ± standard desviation or median [interquartile range]. P-value expresses the differences between men and women
AMI acute myocardial infarction, LVEF left-ventricular ejection fraction, Hb hemoglobin, GFR glomerular filtration rate, HbA1c Glycosylated hemoglobin, LDL low
density lipoprotein, HDL high density lipoprotein
aFamily history: early ischemic heart disease in first-degree relatives
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hemoglobin levels had significantly decreased as com-
pared to baseline (from 7.9 [7.5–8.3] to 7.75 [7.3–8.2] %,
p = 0.02), although with only one third of them (n = 36%)
having their glycosylated hemoglobin levels below
7.5% (Fig. 2). Finally, 120 out of the 201 smokers
(60%) had given up smoking at the end of the follow-
up. Altogether, only 18 out of 311 (5.8%) non-diabetic
and 2 out of 112 (1.8%) diabetic patients met all the
secondary prevention strategy targets at the end of
the 1-year follow-up period.
No clinical variables were associated to an inadequate
control of cardiovascular risk factors, with the exception
of age, which was associated with a lower probability of
inadequate control of HDL-cholesterol (OR = 0.96; 95%
CI: 0.94–0.99; p = 0.005) and triglycerides (OR = 0.96;
95% CI: 0.93–0.99; p = 0.003). Age was also associated
with lower probability of smoking habit continuation
(OR = 0.93; 95% CI: 0.89–0.98; p = 0.004).
Impact of clinical variables and risk factor control on
long-term cardiovascular outcome
Differences in baseline clinical characteristics in patients
with events versus without events (cardiovascular re-
admission or death from any cause) during follow-up
are shown in Table 3.
The median follow-up study period was 20 (11–30)
months. A total of 26 patients (6.1%) died during follow-
up and 42 (9.9%) were readmitted due to cardiovascular
causes. Hospital readmission was due to heart failure in
21 patients, due to acute coronary syndrome in 14, and
due to stroke in 7. Population who were readmitted or
died during follow-up were older, had a higher preva-
lence of systemic hypertension and anemia, scored
higher in the Killip classification and had a lower left
ventricular ejection fraction at hospital-discharge
(Table 3). In the multivariate analysis, hypertension,
Killip class III-IV, anemia and depressed left ventricular
Fig. 2 Control of cardiovascular risk factors during follow-up. In blue it is depicted the percentage of patients in whom a particular cardiovascular
risk factor was not conveniently assessed. In green it is depicted the percentage of patients in whom a particular cardiovascular risk factor is under
control. In red it is depicted the percentage of patients in whom a particular cardiovascular risk factor is out of the targeted range
Table 2 Cardiovascular risk factors distribution at the end of the 1-year follow-up period
Global Men Women p-value
Systolic blood pressure (mmHg) 126 [115–137] 125 [115–136] 130 [116–137] 0.355
Total Cholesterol (mg/dL) 148 [129–175] 146 [127–167] 163 [140–191] <0.001
LDL-Cholesterol (mg/dL) 80 [65–99] 77 [65–93] 90 [67–112] 0.005
HDL-Cholesterol (mg/dL) 44 [38–52] 44 [36–50] 49 [42–57] <0.001
Triglycerides (mg/dL) 105 [81–150] 102 [81–146] 116 [82–158] 0.245
HbA1c (%) (in DM) 7.75 ± 1.84 7.78 ± 1.91 7.68 ± 1.71 0.824
Results are expressed as n (%), mean ± standard desviation or median [interquartile range]. P-value test differences between men and women
LDL low density lipoprotein, HDL high density lipoprotein, HbA1c glycosylated hemoglobin, DM (diabetes mellitus)
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ejection fraction were associated with both, mortality
and cardiovascular readmissions (Table 4).
Regarding the association between inadequate assessment
or control of the conventional cardiovascular risk factors
and long-term cardiovascular mortality and readmission
rates, the lack of assessment of LDL- cholesterol and HDL-
cholesterol were significantly associated with a worse
cardiovascular outcome. No other differences were noted
for other not-assessed or not controlled variables (Table 5).
When only considering patients undergoing primary
PCI (n = 363) or any reperfusion therapy (n = 370), the
long-term adherence to secondary prevention strategies
and its clinical impact were neither significantly
different.
Discussion
In this study it is demonstrated that the long-term
efficiency of conventional secondary prevention strat-
egies after a STEMI episode in the AMI code era (a
therapeutic strategy which enhances a rapid and wide-
spread access to urgent PCI) is manifestly suboptimal.
Impressively, less than 6% of diabetic or non-diabetic
patients met all the secondary prevention strategy
targets at the end of the follow-up period.
Additionally, we have noted that an inadequate assess-
ment of the LDL- and HDL-cholesterol levels is signifi-
cantly associated with a less favorable long-term
cardiovascular outcome after STEMI. Although no other
prognostic impact of an adequate/inadequate risk factors
control was demonstrated in our series, efficacy of second-
ary prevention strategies after a STEMI episode has been
widely proven elsewhere [1–4, 9, 14–20]. It is suggested by
this that an inadequate control of conventional cardiovas-
cular risk factors after a STEMI episode may, at least
partially, counterbalance the demonstrated prognostic
benefits of current myocardial reperfusion strategies, such
as urgent PCI [6–8, 10, 13]. Therefore, further efforts
Table 3 Baseline clinical characteristics of patients with versus






Age (years) 67 ± 15 63 ± 13 0.047
Current smokers 25 (%) 168 (46%) 0.295
Hypertension 44 (72.1%) 186 (51.4%) 0.016
Dyslipidemia 32 (52.5%) 170 (47%) 0.356
Diabetes mellitus 16 (26.2%) 72 (19.9%) 0.273
Family history* 6 (9.8%) 31 (8.6%) 0.946
Chronic kidney disease 3 (4.9%) 11 (3%) 0.448







Anterior 29 (47.5%) 116 (32%)
Inferior 28 (45.9%) 196 (54%)
Killip class <0.001
I 37 (60.6%) 300 (82.9%)
II 9 (14.8%) 30 (8.3%)
III 9 (14.8%) 13 (3.6%)
IV 6 (9.8%) 19 (5.2%)
LVEFa 46.3 ± 12.6 53.1 ± 11.3 <0.001
Event included cardiovascular readmission (due to heart failure, acute
coronary syndrome or stroke) or death from any cause. Results are expressed
as n (%) or mean ± standard deviation
aAMI acute myocardial infarction, LVEF left-ventricular ejection fraction; Family
history: early ischemic heart disease in first-degree relatives
Table 4 Clinical variables associated with mortality and
cardiovascular readmission in multivariate analysis
Mortality HR [CI 95%] p-value
Age 1.02 [0.98–1.06] 0.24
Women 0.89 [0.34–2.30] 0.81
Hypertension 3.73 [1.18–11.82] 0.03
Anemia 3.82 [1.47–9.92] 0.03
Killip class III-IV 5.40 [2.05–14.24] <0.001
LVEF > 45% 0.22 [0.09–0.55] <0.001
Cardiovascular readmission HR [CI 95%] p-value
Age 1.01 [0.98–1.04] 0.42
Women 1.34 [0.70–2.59] 0.38
Hypertension 2.72 [1.26–5.87] 0.01
Anemia 1.39 [0.59–3.29] 0.45
Killip class III-IV 3.56 [1.49–8.49] <0.001
LVEF > 45% 0.37 [0.20–0.69] <0.001
LVEF left-ventricular ejection fraction, HR hazard ratio, CI confidence intervals
Table 5 Age, sex, hypertension, anemia and Killip adjusted
Hazard ratio for mortality or cardiovascular readmission for
those patients with no assessed or with no controlled
cardiovascular risk factors (respect to patients with controlled
risk factors)
HR [CI 95%] p-value
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should be driven in order to enhance a more adequate
accomplishment of all secondary prevention strategies
after a STEMI, since these efforts should have a posi-
tive impact on the cardiovascular outcome in such
patients in the long-term.
Not surprisingly, patients presenting with cardiovascular
readmission or death from any cause during follow-up
were older and had a higher prevalence of systemic hyper-
tension, anemia, scored higher in Killip class classification
and had lower ejection fraction. All of such conventional
risk factors except for age still remain as robust predictors
of a poorer cardiovascular outcome after a STEMI
episode.
Long-term assessment and control of cardiovascular risk
factors after STEMI
Notably, around one-sixth of our patient population did
not undergo a blood test control after the index STEMI
episode, with one third of the diabetic population not
having glycosylated hemoglobin determinations. These
figures are important and highlight the limitations of the
implementation of current secondary prevention
strategies among these patients. Patient education and
physician awareness of this situation are some of the
elements that could be implemented to decrease these
poor results [21].
According to the current European clinical practice
guidelines of secondary prevention, the current objective
for LDL-cholesterol is to achieve a concentration inferior
to 70 mg/dL or a reduction greater than 50% from the
basal LDL-cholesterol levels [18, 19]. In our study, des-
pite a high prescription rate of statins during follow-up,
only one third of our patients reached the targeted
levels. The EUROASPIRE IV (carried out in several
European centers) and ADVANCE studies were under-
taken in patients with stable coronary artery disease, and
neither showed encouraging results [25, 26].
Previously reported European multicenter registers
carried out over nearly two decades in a population of
patients with CAD demonstrated that only half of the
patients have their blood pressure under control despite
of the high prescription rate of ACE inhibitors and beta
blockers [25, 28]. These results are comparable with our
observations, with only 62% of the patients having an ad-
equate blood pressure control, besides the 20% percentage
of the population with blood pressure control not being
adequately assessed. Although a significant decrease in the
systolic blood pressure values was established during
follow-up as compared to the initial value upon hospital
admission for the index STEMI episode (p < 0.001), this
data has to be analyzed cautiously. The initial blood pres-
sure value registered during an acute coronary event is
not necessarily representative of the baseline patient’s
blood pressure control. Furthermore, the prognostic value
of high systolic blood pressure values at admission in the
setting of an acute STEMI remains controversial [29–32].
The observed suboptimal metabolic control of diabetic
patients is in the line of previous observations reported
in series of diabetic patients undergoing by-pass surgery
or PCI, with around one-half of diabetic patients having
inadequate and/or insufficient long-term glycosylated
hemoglobin levels control [27].
Smoking cessation after STEMI is associated with
improved survival rates [14, 33]. Our study confirms an
unacceptably high rate of smoking habit continuation,
thus suggesting that further counseling strategies pursuing
smoking habit withdrawal should be rendered in this
setting.
Myocardial invasive reperfusion and prognosis
The implementation of the AMI code program has in-
creased the access to urgent myocardial reperfusion
to an 87% of STEMI patients, nearly all of them
through PCI [8]. This increase in the use of urgent
reperfusion strategies is similar to that observed in
another national multicenter register, with a reperfu-
sion rate of 85.7% of patients, the difference being
that, in the latter, one third of reperfusions were
performed by means of fibrinolysis [3].
In our study, the 30-day mortality rate (5%) was
similar to that observed in other national and inter-
national surveys in the PCI era [10, 34–39]. However,
6.1% of the STEMI 6-months survivors had deceased
at the end of the 20-months (median) follow-up
period, with an additional 9.9% of cardiovascular
readmissions, percentages that (although low) have to
be still considered suboptimal and in line with previ-
ous national series in which widespread use of urgent
PCI was not yet the rule [3].
Our findings should make us reconsider the actual
therapeutic yield of urgent myocardial reperfusion
strategies in the setting of a STEMI: while the imple-
mentation of assistance networks (such as the AMI
code program) has ameliorated the acute management
of STEMI, the potentially beneficial impact of such
strategies may be jeopardized by a suboptimal long-
term implementation of the secondary prevention strat-
egies. In the view of our results, we believe further
efforts devoted to promote the cessation of smoking,
periodical blood testing and blood pressure control,
and to more intensively maintain LDL-cholesterol,
glycosylated hemoglobin and blood pressure below the
targeted levels should be undertaken. The importance
of an adequate risk factors control has been highlighted
also for patients with stable coronary disease, and may
be specially manifest among patients with low ejection
fraction and (like in our series) with a prior history of
myocardial infarction [40].
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Study limitations
The lack of association between cardiovascular risk factors
control and cardiovascular outcome in our series is prob-
ably due to the low total number of cardiovascular events,
the relatively short follow-up time and the limited sample
size, reducing the statistical power of our analyses. Other-
wise, dose of statins and other medication, adherence to
prescribed treatment, healthy lifestyles such as diet, phys-
ical exercise, and weight control, potentially influencing
the clinical outcome after a STEMI episode, were not
assessed in our series due to limitations inherent to the
use of the regional electronic health recording system.
Finally, our single-center study may not be representative
of the Spanish/European population of STEMI patients.
However, its prospective nature and the consecutive inclu-
sion appear to bestow a representative sample of real life.
Conclusions
Although implementation of the AMI code program has
resulted in a widespread access to urgent myocardial re-
perfusion by means of PCI, the secondary prevention
strategies after a STEMI episode are still far from being
optimal, thus potentially counterbalancing the prognostic
benefits of this therapy. Additional efforts to optimize the
assessment and control of conventional cardiovascular
risk factors should be implemented.
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